EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide–Drug Conjugates in Pancreatic Ductal Adenocarcinoma

Yi Su, Yingxin Lu, Jiahui Yu, Chen Jin, Yi Chen, Wei Lu, Jian Ding

Pharmaceutics · 19.08.2026 · 18 (8) · 1028

DOI: 10.3390/pharmaceutics18081028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 19.08.2026. Verfasst von Yi Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, Shanghai Tekanbio Pharm-Tech Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense extracellular matrix (ECM) with overexpression of extra domain B fibronectin (EDB-FN).

Methods

Herein, we investigated novel albumin-binding peptide–drug conjugates, Mc-ZD2-SN38 and SSC-ZD2-SN38, which integrate the prolonged circulation properties of albumin with the active targeting capability of the ZD2 peptide toward EDB-FN. Covalent and noncovalent albumin-binding strategies extended the half-life by approximately 100-fold and 15-fold, respectively, compared with the non-albumin-binding peptide–drug conjugate (PDC) (ZD2-SN38).

Results

Notably, ZD2-mediated targeting markedly reduced payload accumulation in major organs, resulting in an improved safety profile. In a BxPC-3 xenograft model, Mc-ZD2-SN38 and SSC-ZD2-SN38 demonstrated potent and sustained antitumor efficacy.

Conclusions

These findings establish a long circulation and active targeting drug delivery strategy, providing an ideal framework for the development of PDCs with enhanced therapeutic indices.

Schlagwörter

Stichwörter der Autor:innen

ZD2 peptidealbumin-bindingextra domain B fibronectinpancreatic ductal adenocarcinoma

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
  • Shanghai Tekanbio Pharm-Tech Co., Ltd., Room 4001, Floor 4, Unit 3, Building 8, No. 160, Basheng Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 200131, China.

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Shanghai Tekanbio Pharm-Tech Co., Ltd.
  • National Science and Technology Major Project of the Ministry of Science and Technology of China

Zitieren

APA

Su, Y., Lu, Y., Yu, J., Jin, C., Chen, Y., Lu, W., & Ding, J. (2026). Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide–Drug Conjugates in Pancreatic Ductal Adenocarcinoma. Pharmaceutics, 18(8), 1028. https://doi.org/10.3390/pharmaceutics18081028

Vancouver

Su Y, Lu Y, Yu J, Jin C, Chen Y, Lu W, et al. Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide–Drug Conjugates in Pancreatic Ductal Adenocarcinoma. Pharmaceutics. 2026;18(8):1028. doi:10.3390/pharmaceutics18081028

BibTeX
@article{Su2026,
  author = {Su, Yi and Lu, Yingxin and Yu, Jiahui and Jin, Chen and Chen, Yi and Lu, Wei and Ding, Jian},
  title = {Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide–Drug Conjugates in Pancreatic Ductal Adenocarcinoma},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1028},
  doi = {10.3390/pharmaceutics18081028}
}
Kostenlos starten →